Superstring Capital Management’s Axsome Therapeutics AXSM Stock Holding History

Superstring Capital Management’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.9M	Sell	11,217 -26,216	-70%	-$4.53M	1.35%	24
2025 Q4	$6.84M	Buy	+37,433	New	+$5.23M	3.66%	8
2025 Q1	–	Sell	-4,268	Closed	-$361K	–	35
2024 Q4	$361K	Buy	+4,268	New	+$392K	0.31%	35
2024 Q2	–	Sell	-36,607	Closed	-$2.92M	–	44
2024 Q1	$2.92M	Buy	36,607 +20,428	+126%	+$1.71M	1.93%	17
2023 Q4	$1.29M	Buy	+16,179	New	+$1.08M	0.92%	23

Other funds holding AXSM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Superstring Capital Management's AXSM Position: Q1 2026 in Review

Superstring Capital Management reduced its Axsome Therapeutics (AXSM) stake by 70% in Q1 2026, selling an estimated $4.53M and leaving 11,217 shares worth $1.9M. The position accounts for 1.35% of the portfolio, ranked #24.

Superstring Capital Management first reported a position in AXSM in Q4 2023 and has held it in 5 quarters since. The position peaked at $6.84M in Q4 2025. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

Superstring Capital Management held 11,217 shares of Axsome Therapeutics worth $1.9M as of Q1 2026.
Superstring Capital Management sold 26,216 Axsome Therapeutics shares in Q1 2026, an estimated $4.53M.
Axsome Therapeutics made up 1.35% of Superstring Capital Management's portfolio in Q1 2026, its #24 holding.
Superstring Capital Management first reported a position in Axsome Therapeutics in Q4 2023 and has held it in 5 quarters since.
Superstring Capital Management's Axsome Therapeutics position peaked at $6.84M in Q4 2025.
409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Superstring Capital Management's 13F filing for Q1 2026, filed 14 May 2026.